43,251 Shares in Moderna, Inc. (NASDAQ:MRNA) Acquired by ING Groep NV

ING Groep NV acquired a new stake in shares of Moderna, Inc. (NASDAQ:MRNA) during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 43,251 shares of the company’s stock, valued at approximately $1,798,000.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Blue Trust Inc. lifted its stake in shares of Moderna by 365.6% in the 3rd quarter. Blue Trust Inc. now owns 731 shares of the company’s stock valued at $49,000 after purchasing an additional 574 shares during the last quarter. Raymond James & Associates raised its holdings in Moderna by 19.7% during the third quarter. Raymond James & Associates now owns 162,074 shares of the company’s stock valued at $10,831,000 after buying an additional 26,657 shares in the last quarter. International Assets Investment Management LLC lifted its position in shares of Moderna by 10,687.1% in the third quarter. International Assets Investment Management LLC now owns 319,514 shares of the company’s stock worth $21,353,000 after buying an additional 316,552 shares during the last quarter. Assenagon Asset Management S.A. boosted its stake in shares of Moderna by 79.0% during the 3rd quarter. Assenagon Asset Management S.A. now owns 13,159 shares of the company’s stock worth $879,000 after acquiring an additional 5,807 shares in the last quarter. Finally, E. Ohman J or Asset Management AB bought a new stake in shares of Moderna during the 3rd quarter worth about $942,000. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Up 5.3 %

Shares of NASDAQ MRNA opened at $35.53 on Monday. Moderna, Inc. has a one year low of $29.25 and a one year high of $170.47. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of -3.83 and a beta of 1.59. The business has a fifty day simple moving average of $38.04 and a 200 day simple moving average of $52.46.

Insider Transactions at Moderna

In other news, insider Shannon Thyme Klinger sold 1,418 shares of the business’s stock in a transaction that occurred on Friday, November 29th. The stock was sold at an average price of $42.79, for a total value of $60,676.22. Following the transaction, the insider now directly owns 19,717 shares of the company’s stock, valued at $843,690.43. The trade was a 6.71 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 2,664 shares of company stock valued at $115,210. Corporate insiders own 15.70% of the company’s stock.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. Berenberg Bank boosted their target price on Moderna from $33.00 to $42.00 and gave the stock a “hold” rating in a report on Thursday, January 16th. The Goldman Sachs Group lowered shares of Moderna from a “buy” rating to a “neutral” rating and dropped their price target for the company from $99.00 to $51.00 in a research report on Wednesday, January 29th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $40.00 price objective on shares of Moderna in a report on Tuesday, February 18th. Bank of America dropped their target price on shares of Moderna from $41.00 to $34.00 and set an “underperform” rating on the stock in a report on Tuesday, February 11th. Finally, JPMorgan Chase & Co. set a $45.00 price target on shares of Moderna in a report on Friday, February 14th. Four research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Moderna presently has an average rating of “Hold” and a consensus target price of $60.63.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.